Bullish and bearish opinions expressed in this episode, paired with supporting transcript quotes. The quote confirms what was said—not whether the opinion is correct.
Bullish
$BCI— Brain-computer interface technology is achieving commercial viability with regulatory approval and clear engineering path to improvement. Prima retinal prosthesis received CE approval in Europe and will begin commercial sales, demonstrating BCIs can work better than traditional drug discovery approaches.
$AIMODELS— AI models are discovering true underlying data manifolds and showing alignment with biological neural representations, suggesting they are on the right track toward intelligence. This platonic representation hypothesis indicates AI is not a gimmick and won't hit a wall.
Bearish
$PHARMA— Traditional drug discovery approaches have limited success in neuroscience applications compared to engineering-based BCI approaches. Small molecule drug development is particularly difficult with high failure rates and unclear paths to improvement.